PCORI Final Methods Report Will Detail Public Input, Institute’s Response
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug manufacturers had requested that PCORI list public comments and the Methodology Committee responses in the report, which will establish some of the criteria for reviewing institute research funding applications.
You may also be interested in...
PCORI Critics Emerge As Institute Formally Releases Draft Methods Report
As the Patient-Centered Outcomes Research Institute opens up the public comment period for the draft report created by the institute’s Methodology Committee, criticisms on the direction PCORI is moving are beginning to surface, including accusations that it is becoming just another AHRQ or NIH.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.